Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) - PubMed (original) (raw)
Clinical Trial
. 2015 Dec;173(6):1387-99.
doi: 10.1111/bjd.14164. Epub 2015 Nov 7.
J Cather 2, M Gooderham 3, Y Poulin 4, U Mrowietz 5, C Ferrandiz 6 7, J Crowley 8, C Hu 9, R M Stevens 9, K Shah 9, R M Day 9, G Girolomoni 10, A B Gottlieb 11
Affiliations
- PMID: 26357944
- DOI: 10.1111/bjd.14164
Clinical Trial
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C Paul et al. Br J Dermatol. 2015 Dec.
Abstract
Background: Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses associated with psoriasis.
Objectives: ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for moderate-to-severe plaque psoriasis.
Methods: This phase III, double-blind, placebo-controlled trial randomized adults to apremilast or placebo (2 : 1). At week 16, placebo patients switched to apremilast. At week 32, apremilast patients achieving ≥ 50% reduction in Psoriasis Area and Severity Index (PASI 50) were rerandomized (1 : 1) to continue apremilast or receive placebo. Upon loss of 50% of PASI improvement obtained at week 32, patients rerandomized to placebo resumed apremilast.
Results: The modified intention-to-treat population (full analysis set) included 137 placebo and 274 apremilast patients. At week 16, significantly more apremilast patients achieved PASI 75 (28·8%), PASI 50 (55·5%) and static Physician's Global Assessment score of 0 or 1 (20·4%) vs. placebo (5·8%, 19·7%, 4·4%, respectively; P < 0·001). Most patients rerandomized to apremilast at week 32 had a PASI 50 response at week 52 (80%). Patients treated with apremilast showed significant improvements in quality of life (as assessed by the Dermatology Life Quality Index) and pruritus at week 16 compared with placebo (P < 0·001). The exposure-adjusted incidence of adverse events did not increase with continued apremilast treatment for up to 52 weeks. The most common adverse events were nausea, diarrhoea, nasopharyngitis and upper respiratory tract infection.
Conclusions: Apremilast was effective in the treatment of moderate-to-severe plaque psoriasis over 52 weeks.
© 2015 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Comment in
- Next-generation antipsoriatic drugs: small molecules join.
Gniadecki R. Gniadecki R. Br J Dermatol. 2015 Dec;173(6):1355-6. doi: 10.1111/bjd.14249. Br J Dermatol. 2015. PMID: 26708535 No abstract available.
Similar articles
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Papp K, et al. J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049. J Am Acad Dermatol. 2015. PMID: 26089047 Clinical Trial. - The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J. Reich K, et al. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517. doi: 10.1111/jdv.14015. Epub 2016 Dec 19. J Eur Acad Dermatol Venereol. 2017. PMID: 27768242 Free PMC article. Clinical Trial. - Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Papp K, et al. Lancet. 2012 Aug 25;380(9843):738-46. doi: 10.1016/S0140-6736(12)60642-4. Epub 2012 Jun 29. Lancet. 2012. PMID: 22748702 Clinical Trial. - Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE. Armstrong AW, et al. J Am Acad Dermatol. 2016 Oct;75(4):740-746. doi: 10.1016/j.jaad.2016.05.040. Epub 2016 Jul 28. J Am Acad Dermatol. 2016. PMID: 27476973 Review. - Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Deeks ED. Deeks ED. Drugs. 2015 Aug;75(12):1393-403. doi: 10.1007/s40265-015-0439-1. Drugs. 2015. PMID: 26220911 Review.
Cited by
- [Phosphodiesterase 4 inhibitors in dermatology : Role in the treatment of skin diseases].
Schmidt MF, Albuscheit N, Yazdi AS. Schmidt MF, et al. Dermatologie (Heidelb). 2024 Oct;75(10):791-797. doi: 10.1007/s00105-024-05407-7. Epub 2024 Aug 30. Dermatologie (Heidelb). 2024. PMID: 39212723 Review. German. - Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of apremilast.
Barbarroja N, López-Medina C, Escudero-Contreras A, Arias-de la Rosa I. Barbarroja N, et al. Front Immunol. 2024 Aug 7;15:1459185. doi: 10.3389/fimmu.2024.1459185. eCollection 2024. Front Immunol. 2024. PMID: 39170613 Free PMC article. Review. - Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.
Okubo Y, Terui T, Kobayashi S, Sano S, Morita A, Imafuku S, Tada Y, Abe M, Yaguchi M, Kimura T, Shimauchi J, Zhang W, Amouzadeh H, Murakami M. Okubo Y, et al. Dermatol Ther (Heidelb). 2024 Jul;14(7):1863-1873. doi: 10.1007/s13555-024-01195-z. Epub 2024 Jun 19. Dermatol Ther (Heidelb). 2024. PMID: 38896381 Free PMC article. - Therapeutic perspectives on PDE4B inhibition in adipose tissue dysfunction and chronic liver injury.
Staller DW, Bennett RG, Mahato RI. Staller DW, et al. Expert Opin Ther Targets. 2024 Jul;28(7):545-573. doi: 10.1080/14728222.2024.2369590. Epub 2024 Jun 19. Expert Opin Ther Targets. 2024. PMID: 38878273 Review. - Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from PROMINENT.
Abe M, Okubo Y, Takahashi H, Endo K, Chaudhari S, Deignan C, Amouzadeh H, Hino R. Abe M, et al. Dermatol Ther (Heidelb). 2024 Jun;14(6):1587-1597. doi: 10.1007/s13555-024-01179-z. Epub 2024 May 27. Dermatol Ther (Heidelb). 2024. PMID: 38801606 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical